Surgically Unresectable Metastatic Colorectal Cancer Case: 2

Video

Surgically Unresectable Metastatic Colorectal Cancer

  • A 47-year-old male presented to the doctor with abdominal pain and anemia
  • He has a family history of cancer:
    • His brother was diagnosed with colon cancer at age 44
    • His sister was diagnosed with gastric cancer at age 24, and mother was diagnosed with endometrial cancer at age 50
    • He has 2 children, a 15-year old boy and a 10-year old girl
  • Initial lab evaluations showed anemia (Hb 8.0 g/dL) and elevated carcinoembryonic antigen (980 ng/ml)
  • CT-scan showed a large mass in the ascending colon and diffuse liver nodules
  • Biopsy results showed a moderately differentiated adenocarcinoma
    • Microsatellite instability (MSI) testing revealed MSI-high (MSI-H) tumor and IHC confirmed the absence of expression of the MLH1 protein
    • He was referred for genetic testing
  • The patient was diagnosed with hereditary nonpolyposis colorectal cancer syndrome
Recent Videos
Jamie L. Koprivnikar, MD, an expert on MDS
Jamie L. Koprivnikar, MD, an expert on MDS
Jamie L. Koprivnikar, MD, an expert on MDS
Jamie L. Koprivnikar, MD, an expert on MDS
Jamie L. Koprivnikar, MD, an expert on MDS
Jamie L. Koprivnikar, MD, an expert on MDS
Jamie L. Koprivnikar, MD, an expert on MDS
Jamie L. Koprivnikar, MD, an expert on MDS
Solly Chedid, MD, an expert on MDS
Related Content
Invikafusp Alfa Shows Potential in PD-1 Refractory Solid Tumors

Invikafusp Alfa Shows Potential in PD-1 Refractory Solid Tumors

Jordyn Sava
November 21st 2024
Article

Invikafusp alfa showed promise as a treatment option across a range of high tumor mutational burden cancers or virally associated malignancies.

Read More

Behind the FDA Approval of Fruquintinib for Previously Treated mCRC

Behind the FDA Approval of Fruquintinib for Previously Treated mCRC

Jordyn Sava;Arvind Dasari, MD, MS
November 15th 2023
Podcast

In season 4, episode 18 of Targeted Talks, Arvind Dasari, MD, MS, dives into the recent approval of fruquintinib for patients with metastatic colorectal cancer.

Listen

FDA Approves Cologuard Plus Stool DNA Test for Colorectal Cancer Screening

FDA Approves Cologuard Plus Stool DNA Test for Colorectal Cancer Screening

Sabrina Serani
October 4th 2024
Article

The noninvasive test provides a beneficial screening tool for patients 45 and older at average risk for colorectal cancer.

Read More

Special Episode: Insight on Targeting Rare Genomic Alterations in Colorectal Cancers

Special Episode: Insight on Targeting Rare Genomic Alterations in Colorectal Cancers

Michael J. Overman, MD;Nichole Tucker
July 15th 2021
Podcast

In season 2, episode 6 of Targeted Talks, Dr. Michael J. Overman, joins Targeted Oncology for a special discussion around rare genomic alterations in colorectal cancer

Listen

No Survival Advantage Seen With Ramucirumab and TAS-102 in Metastatic Colorectal Cancer

No Survival Advantage Seen With Ramucirumab and TAS-102 in Metastatic Colorectal Cancer

Caroline Seymour
September 15th 2024
Article

The combination of ramucirumab with trifluridine/tipiracil failed to show improvements in overall survival vs TAS-102 alone in heavily pretreated metastatic colorectal cancer.

Read More

Phase 3 Trials of Botensilimab/Balstilimab Move Forward, Despite FDA's Approval Setback

Phase 3 Trials of Botensilimab/Balstilimab Move Forward, Despite FDA's Approval Setback

Jordyn Sava
July 18th 2024
Article

Agenus was advised by the FDA against filing for accelerated approval of botensilimab plus balstilimab for relapsed/refractory microsatellite stable metastatic colorectal cancer without liver metastases.

Read More